# US 2002/0001829 A1 · Method for large scale plasmid purification

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2002/0001829 A1
- Document ID: US20020001829A1
- Status: Published application
- Kind: A1
- Application number: 09/799,906
- Filed: 2001-03-06
- Published: 2002-01-03
- Earliest claimed: 1994-07-15
- Assignees: Merck & Co., Inc.
- Inventors: Ann L. Lee; Sangeetha Sagar
- Web page: https://patentgrep.com/patent/US20020001829A1

## CPC

- C12N 15/1017: {by filtration, e.g. using filters, frits, membranes}
- C12N 1/06: Lysis of microorganisms
- C12N 15/10: Processes for the isolation, preparation or purification of DNA or RNA (chemical preparation of DNA or RNA C07H21/00; preparation of non-structural polynucleotides from microorganisms or with enzymes C12P19/34)
- C12N 15/1006: {by means of a solid support carrier, e.g. particles, polymers}
- C12N 15/101: {by chromatography, e.g. electrophoresis, ion-exchange, reverse phase}
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

A process is disclosed for the large scale isolation and purification of plasmid DNA from large scale microbial fermentations. All three forms of plasmid DNA; supercoil (form I), nicked or relaxed circle (form II), and linearized (form III), are individually isolatable using the disclosed process. Highly purified DNA suitable for inclusion in a pharmaceutical composition is provided by the disclosed process.

## Claims

### Claim 1

A process for large scale isolation and purification of plasmid DNA from large scale microbial cell fermentations, comprising:
a) harvesting microbial cells from a large scale fermentation;
b) adding to the harvested microbial cells a sufficient amount of a lysis solution;
c) heating the microbial cells of step b) to a temperature between 70° C. and 100° C. in a flow-through heat exchanger to form a crude lysate;
d) centrifuging the crude lysate;
e) filtering and diafiltering the supernatant of step d) providing a filtrate;
f) contacting the filtrate of step e) with an anion exchange matrix;
g) eluting and collecting plasmid DNA from the anion exchange matrix;
h) contacting the plasmid DNA from step g) with a reversed phase high performance liquid chromatography matrix;
i) eluting and collecting the plasmid from the reversed phase high performance liquid chromatography matrix of step h);
j) optionally concentrating and/or diafiltering the product of step i) into a pharmaceutically acceptable carrier; and
k) optionally sterilizing the DNA product.

### Claim 2 (depends on 1)

The process of claim 1 wherein the lysis solution of step b) is modified STET buffer.

### Claim 3 (depends on 1)

The process of claim 1 wherein the heating of step c) is to a temperature between 70° C. and 77° C.

### Claim 4 (depends on 1)

The process of claim 1 wherein the lysis solution of step b) contains a sub-microgram concentration of lysozyme.

### Claim 5 (depends on 1)

The process of claim 1 optionally including RNase treatment at any step following step a).

### Claim 6 (depends on 1)

An isolated and purified plasmid DNA obtained by the process of claim 1.

### Claim 7 (depends on 6)

The plasmid DNA of claim 6 wherein said plasmid is suitable for administration to humans.

### Claim 8 (depends on 6)

The plasmid DNA of claim 6 wherein said plasmid is suitable for administration to non-human animals.

### Claim 9 (depends on 6)

The plasmid DNA of claim 6 wherein said plasmid is a polynucleotide vaccine.

### Claim 10

An isolated and purified plasmid DNA suitable for administration to humans.

### Claim 11 (depends on 10)

The plasmid DNA of claim 10 wherein said plasmid DNA is a polynucleotide vaccine.
